(b) FDA may refuse to grant a request for MUMS-drug designation if the request for designation contains an untrue statement of material fact or omits material information.

§ 516.26 Amendment to MUMS-drug designation.

- (a) At any time prior to conditional approval or approval of an application for a MUMS-designated drug, the sponsor may apply for an amendment to the designated intended use if the proposed change is due to new and unexpected findings in research on the drug, information arising from FDA recommendations, or other unforeseen developments.
- (b) FDA will grant the amendment if it finds:
- (1) That the initial designation request was made in good faith;
- (2) That the amendment is intended to make the MUMS-drug designated intended use conform to the results of new and unexpected findings in research on the drug, information arising from FDA recommendations, or other unforeseen developments; and
- (3) In the case of a minor use, that as of the date of the submission of the amendment request, the amendment would not result in the intended use of the drug no longer being considered a minor use.

§516.27 Change in sponsorship.

- (a) A sponsor may transfer sponsorship of a MUMS-designated drug to another person. A change of sponsorship will also transfer the designation status of the drug which will remain in effect for the new sponsor subject to the same conditions applicable to the former sponsor provided that at the time of a potential transfer, the new and former sponsors submit the following information in writing and obtain permission from FDA:
- (1) The former sponsor shall submit a letter to FDA that documents the transfer of sponsorship of the MUMS-designated drug. This letter shall specify the date of the transfer. The former sponsor shall also certify in writing to FDA that a complete copy of the request for MUMS-drug designation, including any amendments to the request, and correspondence relevant to

the MUMS-drug designation, has been provided to the new sponsor.

- (2) The new sponsor shall submit a letter or other document containing the following information:
- (i) A statement accepting the MUMS-drug designated file or application;
- (ii) The date that the change in sponsorship is intended to be effective;
- (iii) A statement that the new sponsor has a complete copy of the request for MUMS-drug designation, including any amendments to the request and any correspondence relevant to the MUMS-drug designation;
- (iv) A statement that the new sponsor understands and accepts the responsibilities of a sponsor of a MUMS-designated drug established elsewhere in this subpart;
- (v) The name and address of a new primary contact person or permanent resident U.S. agent; and
- (vi) Evidence that the new sponsor is capable of actively pursuing approval with due diligence.
- (b) No sponsor may relieve itself of responsibilities under the act or under this subpart by assigning rights to another person without:
- (1) Assuring that the new sponsor will carry out such responsibilities; and
- (2) Obtaining prior permission from FDA.

§516.28 Publication of MUMS-drug designations.

- FDA will periodically update a publicly available list of MUMS-designated drugs. This list will be placed on file at the FDA Division of Dockets Management, and will contain the following information for each MUMS-designated drug:
- (a) The name and address of the sponsor:
- (b) The established name and trade name, if any, of the drug;
 - (c) The dosage form of the drug;
- (d) The species and the proposed intended use for which MUMS-drug designation was granted; and
- (e) The date designation was granted.

§ 516.29 Termination of MUMS-drug designation.

(a) The sponsor of a MUMS-designated drug must notify FDA of any